FY2027 Earnings Forecast for THTX Issued By Leede Financial

Theratechnologies Inc. (NASDAQ:THTX) – Analysts at Leede Financial issued their FY2027 earnings per share (EPS) estimates for shares of Theratechnologies in a research report issued to clients and investors on Wednesday, February 26th. Leede Financial analyst D. Loe anticipates that the company will post earnings of $0.23 per share for the year. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2027 earnings at $0.23 EPS.

Separately, Research Capitl upgraded shares of Theratechnologies to a “strong-buy” rating in a research note on Friday, February 14th.

Theratechnologies Stock Performance

Shares of THTX stock opened at $1.62 on Friday. The company has a market capitalization of $74.49 million, a price-to-earnings ratio of -16.20 and a beta of 1.26. The company’s 50-day moving average is $1.74 and its 200 day moving average is $1.45. Theratechnologies has a one year low of $1.08 and a one year high of $2.18.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. National Bank of Canada FI raised its position in shares of Theratechnologies by 29.4% during the 3rd quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock valued at $232,000 after purchasing an additional 42,435 shares during the period. Harbour Investments Inc. increased its holdings in Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock valued at $159,000 after acquiring an additional 14,655 shares during the last quarter. Wealthspire Advisors LLC boosted its holdings in shares of Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock valued at $129,000 after purchasing an additional 20,000 shares during the last quarter. Hillsdale Investment Management Inc. purchased a new position in Theratechnologies during the 4th quarter valued at approximately $108,000. Finally, Virtu Financial LLC bought a new stake in Theratechnologies in the 4th quarter worth approximately $40,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.